Pluristem prices $32m offering to progress stem cell therapies
This article was originally published in Scrip
Allogeneic stem cell therapy developer Pluristem Therapeutics priced an offering of eight million units - each consisting of one share of common stock share and a warrant to purchase 35% of one share - at $4 per unit for gross proceeds of $32 million to finance research and development, including clinical trials.
You may also be interested in...
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.